Mariia S. Zhuravleva

Mariia S. Zhuravleva

Auto-generated profile, based on publicly available information

Mariia S. Zhuravleva

Mechnikov North-Western State Medical University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
IBIgor G. Bakulin
Igor G. Bakulin
AZA.V. Zharkov
A.V. Zharkov
MZM.S. Zhuravleva
M.S. Zhuravleva
MSM.YU. Serkova
M.YU. Serkova
Due to the globally stable high rates of colorectal cancer prevalence, incidence, and mortality, improving the screening program is a priority for the healthcare system both in the Russian Federation and abroad. Objective. To assess the coverage of the Leningrad region population with the colorectal cancer screening program in 2022 as part of medical check-ups carried out following the Order of the Ministry of Health of the Russian Federation dated April 27, 2021 No. 404n «On approval of the procedure for preventive medical check-ups for certain groups of the adult population.» Material and methods. In 2022, among the population of the Leningrad Region, 331.757 subjects aged 40 to 64 years old and 329.956 subjects aged 65 years old were subject to medical check-ups. The coverage of the population with the screening program was analyzed using descriptive statistics. Results. At stage 1 of the medical check-up, 83.650 fecal occult blood tests were performed, accounting for 12.6% of the population’s involvement in screening. Of these 83.650 fecal occult blood tests, an immunochemical method was used in 62.063 (74%) cases and a biochemical test in 21.587 (26%) cases. A positive result was obtained in 4797 (5.7%) subjects; a colonoscopy was performed in 2009 (42%) of them. Conclusion. The ways to improve the detection of precancerous diseases and reduce the incidence of colorectal cancer include coverage of at least 80% of the population with stage 1 screening, the use of only immunochemical tests for occult blood, achieving of the proportion of abnormalities according to immunochemical feces test of at least 4%, colonoscopy coverage of at least 70% of individuals with positive results of a fecal occult blood test, good preparation of patients for an endoscopic procedure, and improvement of the endoscopic technique.

21 May 2023 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
LLL. B. Lazebnik
L. B. Lazebnik
IBIgor G. Bakulin
Igor G. Bakulin
ESE. V. Skazyvaeva
E. V. Skazyvaeva
NBN. V. Bakulina
N. V. Bakulina
AKAnatoly Khavkin
Anatoly Khavkin
Clinical guidelines are intended for gastroenterologists, internists, and general practitioners and focus primarily on the management of patients with symptomatic uncomplicated diverticular disease, as well as on the primary and secondary prevention of acute diverticulitis and other complications of diverticular disease. Clinical guidelines were developed by the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientifi c Society of Russia, and the North-West Society of Gastroenterologists and Hepatologists. One of the reasons for creating new clinical guidelines is that the current guidelines on diverticular disease (2021) pay much more attention to complications of diverticular disease and surgical treatment of acute and chronic complications of the disease.

15 August 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
IBIgor G. Bakulin
Igor G. Bakulin
MSMaria Skalinskaya
Maria Skalinskaya
IMIgor V. Maev
Igor V. Maev
ESEkaterina V. Skazyvaeva
Ekaterina V. Skazyvaeva
MZMariia S. Zhuravleva
Mariia S. Zhuravleva
СИСкалинская Мария Игоревна
Скалинская Мария Игоревна
Treatment of inflammatory bowel diseases IBD (Crohns disease, ulcerative colitis) is aimed at achieving clinical, endoscopic and histological remission, minimizing surgical complications, and ensuring a normal quality of life. However, the use of medical treatment is potentially associated with various adverse events, among which infectious complications, malignant neoplasms, as well as myelotoxicity, hepatotoxicity, skin lesions and others. The risk of side effects depends on the type of drug therapy (5-aminosalicylates, thiopurines, biologicals, etc.), the duration of treatment, the presence of extra-intestinal manifestations, etc. The article provides an overview of data on both the effectiveness and frequency of various side effects of the main classes of drugs in IBD, presents methods of investigation which can predict the effectiveness and development of side effects, the implementation of which can be considered as a variant of personalized therapy in IBD.

21 May 2023 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
LLL. B. Lazebnik
L. B. Lazebnik
IBIgor G. Bakulin
Igor G. Bakulin
MZM. S. Zhuravleva
M. S. Zhuravleva
NBN. V. Bakulina
N. V. Bakulina
ЮКЮ. Г. Кузнецова
Ю. Г. Кузнецова
Clostridioides difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea, and an important cause of nosocomial infection. Since the publication of the National Guidelines (2016, 2017), new data have been accumulated on the genetic structure and pathogenic properties of the most common causative agent of severe forms of antibiotic- associated diarrhea, which has led to the reclassifi cation of the pathogen, formerly known as Clostridium diffi cile, to Clostridioides difficile. Laboratory algorithms have been developed to diagnose CDI and determine the toxigenicity of strains reliably. New data on the effectiveness of antibacterials have been published, monoclonal antibodies to toxin B (bezlotoxumab) have been introduced into clinical practice to prevent CDI recurrence, and fecal microbiota transplantation has been proposed. Over the past 5 years, many international guidelines on the management of adult patients with CDI have also been updated (USA, EU). In the last decade, including due to the COVID-19 pandemic, there has been an increase in CDI incidence. Considering therelevance of CDI, new data on the pathogen, and domestic features, the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North-West Society of Gastroenterologists and Hepatologists developed these clinical guidelines.

1 November 2019 in Therapy
Verified
Journal Article
Closed access
IBIgor G. Bakulin
Igor G. Bakulin
AAAbatsieva M. P. Abatsieva
Abatsieva M. P. Abatsieva
MSMaria Skalinskaya
Maria Skalinskaya
ZZZhuravleva M.S. Zhuravleva
Zhuravleva M.S. Zhuravleva

21 March 2022 in Therapy
Verified
Journal Article
Closed access
IBIgor G. Bakulin
Igor G. Bakulin
MSMaria Skalinskaya
Maria Skalinskaya
SSSkazyvaeva E.V. Skazyvaeva
Skazyvaeva E.V. Skazyvaeva
RRRasmagina I.A. Rasmagina
Rasmagina I.A. Rasmagina
ZZZhuravleva M.S. Zhuravleva
Zhuravleva M.S. Zhuravleva
UUUsachev R.A. Usachev
Usachev R.A. Usachev